Last updated: 20 May 2024 at 8:09pm EST

Dr. Remy Durand Ph.D. Net Worth




The estimated Net Worth of Remy Durand is at least $8.67 Milion dollars as of 8 May 2024. Dr Durand owns over 95,288 units of Alpine Immune Sciences Inc stock worth over $8,666,478 and over the last few years he sold ALPN stock worth over $0.

Dr D ALPN stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Alpine Immune Sciences Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 95,288 units of ALPN stock worth $513,602 on 8 May 2024.

The largest trade he's ever made was exercising 95,288 units of Alpine Immune Sciences Inc stock on 8 May 2024 worth over $513,602. On average, Dr trades about 31,763 units every 0 days since 2024. As of 8 May 2024 he still owns at least 133,392 units of Alpine Immune Sciences Inc stock.

You can see the complete history of Dr Durand stock trades at the bottom of the page.





Dr. Remy Durand Ph.D. biography

Dr. Remy Durand Ph.D. is the Chief Bus. Officer at Alpine Immune Sciences Inc.



What's Dr D's mailing address?

Remy's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.

Insiders trading at Alpine Immune Sciences Inc

Over the last 7 years, insiders at Alpine Immune Sciences Inc have traded over $91,012,519 worth of Alpine Immune Sciences Inc stock and bought 8,061,426 units worth $69,477,679 . The most active insiders traders include Peter A. Thompson, Advisors Llc Orbi Med Capit... a James N Topper. On average, Alpine Immune Sciences Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,201,670. The most recent stock trade was executed by Stanford L Peng on 8 May 2024, trading 271,792 units of ALPN stock currently worth $668,608.



What does Alpine Immune Sciences Inc do?

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.



Complete history of Dr Durand stock trades at Alpine Immune Sciences Inc

Osoba
Trans.
Transakce
Celková cena
Remy Durand
Chief Business Officer
Využití opce $513,602
8 May 2024


Alpine Immune Sciences Inc executives and stock owners

Alpine Immune Sciences Inc executives and other stock owners filed with the SEC include: